Products

  1. Home
  2. Products
  3. Bone & Mineral Metabolism
  4. IDKmonitor® Infliximab Drug Level ELISA

IDKmonitor® Infliximab Drug Level ELISA

$946.00

In Stock

Method: ELISA
Sample Type (Matrix): Serum, EDTA Plasma
Sample Volume: 10 µl
Species: Human
Incubation time: 2h 10m
Standard Range: 4.15-225 ng/ml
Size: 96 wells
Regulatory Status: For research use only in the U.S.
Kit Manual: Download

The IDKmonitor® Infliximab Drug Level ELISA is an enzyme immunoassay intended for the quantitative determination of free therapeutic TNFα antibodies infliximab (e.g. REMICADE®, Remsima®, Inflectra®) in EDTA plasma and serum.

For research use only. Not for use in diagnostic procedures.

For Laboratory Professional Use Only.

This is the RUO version of Immundiagnostik part number K 9655.

Test Principle of the IDKmonitor® Infliximab Drug Level ELISA

This ELISA is designed to determine the quantity of free infliximab (therapeutic antibody against TNFα) in EDTA plasma or serum samples.

In the first incubation step, the free infliximab from the sample is bound to the specific monoclonal anti-infliximab antibody coated on the plate. To remove all unbound substances, a washing step is carried out. In a further incubation step, a peroxidase-labeled antibody is added. Tetramethylbenzidine (TMB) is used as a substrate for peroxidase. Finally, an acidic stop solution is added to terminate the reaction.

The color changes from blue to yellow. The intensity of the yellow color is directly proportional to the concentration of free infliximab in the sample. A dose-response curve of the absorbance unit (optical density, OD) vs. concentration is generated, using the values obtained from the standard. The concentrations of free infliximab in the samples are determined directly from this curve.

 

Additional information

Weight 35.5 oz
Dimensions 6.5 × 10 × 4.5 in
Social media & sharing icons powered by UltimatelySocial

Become an IDK Insider!

Join our mailing list to receive the latest news and updates from Immundiagnostik, Inc.

 
 
 
 

You have Successfully Subscribed!